Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70015 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Hongying You und 13 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suz…. Hauptthemen laut MEDLINE: Multiple Myeloma, Chromosomes, Human, Pair 1, Chromosome Deletion. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Translational Research Grant of NCRCH, Suzhou Project of Science and Technology 2021, Jiangsu Province Science and Technology Resources (Major Disease Biological Samples) Coordination Service Platform 2022 Open Project.
Abstract (Originalsprache)
Del(1p32.3) by FISH detection in multiple myeloma (MM) has not been routinely carried out in China. Its clinical significance was not clearly demonstrated. This study analysed clinical characteristics, treatment response and prognostic significance of del(1p32.3). We analysed 345 newly diagnosed multiple myeloma (NDMM) samples, and cytogenetic analysis was performed using Cytoscan and FISH results, enabling comprehensive disease‐specific cohort analysis and prognostic model development. The total proportion of chromosomal 1 abnormality was 64.1%, including 189 cases of 1q21 gain/amplification and 88 cases of 1p deletion, 40 patients had 1p32.3/CDKN2Cdeletion. Del(1p32.3) patients were strongly correlated with 1q21 gain/amplification and 17p deletion. Del(1p32.3) patients were more likely accompanied with extra‐medullary multiple myeloma (EMM) and complex karyotype. Del(1p32.3) had a worse effect on progression‐free survival (PFS) and overall survival (OS), alongside other high‐risk cytogenetic abnormalities that further worsened prognosis, especially 1q gain/amplification. Patients with 1p32.3 in the main clone or with a single monoallelic deletion had significantly poorer survival outcomes. Autologous stem cell transplantation (ASCT) cannot completely overcome its adverse effects on prognosis. In multivariate analysis, 1p32.3 was an important independent adverse PFS factor. Patients harbouring single monoallelic del(1p32.3) and/or main clone deletions demonstrated inferior outcomes despite lenalidomide, bortezomib and dexamethasone (VRD) induction and transplantation. Del(1p32.3) had synergistic effects frequently co‐occurring with 1q21 gain/amplification, thus, we strongly advocate for routine del(1p32.3) testing in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
ORCID-Profile: Lingzhi Yan, Yingying Zhai, Jingjing Shang, Song Jin, Jinlan Pan, Chengcheng Fu
Förderung
- Translational Research Grant of NCRCH
- Suzhou Project of Science and Technology 2021
- Jiangsu Province Science and Technology Resources (Major Disease Biological Samples) Coordination Service Platform 2022 Open Project
- National Natural Science Foundation of China General Project Approval 2022
- Young Scientists Fund of the Natural Science Foundation of Jiangsu Province
Zitieren
APA
You, H., Yao, W., Yan, L., Zhai, Y., Yan, Z., Shang, J., Yan, S., Shi, X., Jin, S., Ge, X., Shen, H., Pan, J., Wu, D., & Fu, C. (2025). Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone. British Journal of Haematology. https://doi.org/10.1111/bjh.70015
Vancouver
You H, Yao W, Yan L, Zhai Y, Yan Z, Shang J, et al. Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone. British Journal of Haematology. 2025. doi:10.1111/bjh.70015
BibTeX
@article{You2025,
author = {You, Hongying and Yao, Weiqin and Yan, Lingzhi and Zhai, Yingying and Yan, Zhi and Shang, Jingjing and Yan, Shuang and Shi, Xiaolan and Jin, Song and Ge, Xinxin and Shen, Hongjie and Pan, Jinlan and Wu, Depei and Fu, Chengcheng},
title = {Poor prognosis of newly diagnosed multiple myeloma patients with 1p32.3 deletion in single monoallelic deletion and/or in main clone},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70015}
}
EUVIMED